Litigation Details for Cipla Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Cipla Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Docket		Date Filed	2019-01-08
Court	District Court, D. Delaware	Date Terminated	2020-08-17
Cause	15:1 Antitrust Litigation	Assigned To	Leonard Philip Stark
Jury Demand	Plaintiff	Referred To
Patents	6,011,068; 7,232,818; 7,417,042; 7,491,704; 7,737,112; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297; 9,375,405
Link to Docket	External link to docket

Details for Cipla Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-03-13	132	Redacted Document	license to Amgen’s United States Patent No. 9,375,405 (the “’405 patent”) under its settlement agreement…doctrine of patent misuse “is about . . . ‘patent leverage,’ i.e., the use of the patent power to impose…agreement into the doctrine of patent misuse is equally unavailing. Although patent misuse is not a cause of…Del. 2010) (“Patent misuse is an affirmative defense.”). In its complaint, Cipla pled patent misuse as …premised on “patent misuse,” however, the Amgen-Teva agreement does not constitute patent misuse as a	External link to document
2019-03-13	145	Redacted Document	infringing U.S. Patent Nos. 7,232,818 (the ’818 Patent), 7,417,042 (the ’042 Patent), 7,491,704 (the …704 Patent), 7,737,112 (the ’112 Patent), 8,129,346 (the ’346 Patent), 8,207,125 (the ’125 Patent), 8,…8,207,126 (the ’126 Patent), 8,207,127 (the ’127 Patent) and 8,207,297 (the ’297 Patent). By joint stipulation…Court) for infringement of our U.S. Patent No. 9,375,405 (the ’405 Patent) against a number of manufacturers… of the ’405 Patent. On September 18, 2018, Accord denied infringement of the ’405 Patent and alleged	External link to document
2019-03-25	168	Exhibit A	ied the claimed invention of U.S. Patent No. 9,375,405 (the “’405 Patent”). 55. The purpose of the January…that the courts will not aid a patent owner who has misused his patents to recover any of their emoluments…first counterclaim on grounds of patent misuse. Amgen is wrong. The patent misuse complained of by Cipla …claimed invention of the ’405 Patent. In these circumstances, it was per se patent misuse for Amgen to condition…of licensed patent); cf. Kimble v. Marvel Entm’t, LLC, 135 S. Ct. 2401, 2411 (2015) (patent license requiring	External link to document
2019-05-02	186	Memorandum Opinion	expiration of United States Patent No. 9,375,405 (the '"405 patent"), which is owned by …Product infringes the '405 patent, (ii) the claims of the '405 patent are valid and enforceable, …;405 patent 4:15-25) Amgen markets a branded drug, SENSIPAR®, that practices the '405 patent. (D.…on the merits of the United States Patent and Trademark Office Patent Trial and Appeal Board from which…on the merits of the United States Patent and Trademark Office Patent Trial and Appeal Board." (Amgen-Cipla	External link to document
2019-10-21	246	Redacted Document	ONGOING PATENT INFRINGEMENT LITIGATION Amgen holds United States Patent No. 9,375,405 (the “‘…ONGOING PATENT INFRINGEMENT LITIGATION Amgen holds United States Patent No. 9,375,405 (the “‘…............................ 3 I. THE ONGOING PATENT INFRINGEMENT LITIGATION. ......................…Teva, and other pharmaceutical manufacturers for patent infringement stemming from those manufacturers’…“‘405 patent”), which describes and claims pharmaceutical compositions comprising cinacalcet hydrochloride	External link to document